Project Grant R43HL177843
Award Date
2/1/25
Completion Date
1/31/26
Dollars Obligated
$348K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $288,986 to Biotherapeutics, Inc., a biotechnology company in Blacksburg, VA. The grant supports the development of a novel oral immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) Determine the safety profile and pharmacokinetics of the new therapeutic in rats, and 2) Characterize the therapeutic...
This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Parmedics, Inc., a for-profit, woman-owned biotechnology company, for the development of small molecule protease-activated receptor-2 (PAR2) antagonists as potential oral therapeutics for asthma. The goal is to characterize two novel PAR2 antagonists, C937 and C938, with improved pharmacodynamics and pharmacokinetics to enable...
This Project Grant award, totaling $834,840.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The funding will support research to emulate hypothetical randomized and adaptive trials in order to evaluate the comparative effectiveness of biologics in treating patients with severe asthma. The research team at Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, will...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $320,863 to Aaiit LLC (DBA: Inflammation Immuno Therapy) for the development of a bifunctional IgE antagonist and dissociator (ANDI) therapeutic to treat severe allergic asthma. The key goals of the project are to humanize the ANDI nanobody, evaluate its long-term tolerability, and assess its efficacy in an...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $760,759 to the University of Illinois to study the immunoregulatory role of a specific dendritic cell subset, CX3CR1+CDC2, in resolving allergic lung inflammation associated with asthma. The key objectives are to characterize the anti-inflammatory functions of the CX3CR1+CDC2 subset, determine how it regulates T regulatory cell...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $863,328 to Aquillius Corp to develop a wearable graphene respiratory sensor for early detection and continuous monitoring of asthma. The goal is to create a cost-effective, robust device suitable for all ages that can measure pulmonary functions in real-time to improve patient monitoring, treatment, and diagnosis of asthma. The Phase I...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,016,357 to study the role of the transmembrane protein TMEM178 in regulating lung inflammation and asthma pathogenesis. The key objectives are to: 1) Characterize how TMEM178 inhibits calcium signaling and inflammatory responses in bronchial epithelial cells, 2) Assess the impact of targeted TMEM178 deletion in epithelial cells on lung...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $387,116 to the University of South Florida to research the sensory neuronal mechanisms underlying the development of house dust mite-induced airway hyperreactivity, a key characteristic of asthma. The 5-year award, effective May 1, 2025, aims to identify the specific nerve subtypes and signaling pathways activated by house dust mite...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $604,750 to Scientific Horizons Consulting LLC to develop and evaluate a novel inhalation device prototype for the pulmonary delivery of anti-inflammatory agents to treat inflammation and pain associated with chronic obstructive pulmonary disease (COPD). The key objectives are to: 1) investigate the feasibility of delivering...